The benefits of transient lymphodepletion prior to cell infusion are observed in an ongoing trial at the University of Pennsylvania where patients with myeloma who received autologous CD3/CD28-costimulated T cells 2 days after Busulfan showed improved engraftment compared to patients where T cells were given 12 days after chemotherapy [52,53]. This evidence concerns the gene CD28 and plasma cell myeloma.